BMS Archive

Fungi · Scientific monograph

Schizophyllum commune

Split Gill Fungus

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Immunological Research, Cellular & Immune Studies, Inflammatory Pathways

Research overview

Historical use

Consumed as food in parts of Asia, Africa, and Latin America. Used in traditional medicine in Mexico and Southeast Asia for fever, headache, and infections. One of the most widespread mushroom species globally (found on every continent except Antarctica). Not traditionally prominent in Chinese or Japanese medicinal systems, but significant in modern Japanese oncology research.

Modern research context

Schizophyllan (SPG / Sonifilan / sizofiran) — a beta-1,3-glucan — is approved in Japan as an adjunct to radiation therapy in cervical cancer, with clinical trials demonstrating improved survival [1]. Efficacy as an immunotherapy adjunct has also been studied in advanced gastric cancer [2]. Immunomodulatory mechanisms include enhancement of NK cell and macrophage activity [3]. Importantly, S. commune is also an opportunistic pathogen capable of causing allergic bronchopulmonary mycosis and sino-pulmonary infections in immunocompromised hosts [4][5]. Antifungal properties are noted in vitro.

Adverse effects

IV/intratumoral administration: local injection reactions, mild fever. Oral use: generally well tolerated. Note: can cause opportunistic infections (schizophyllosis) in severely immunocompromised patients.

Contraindications

Severe immunocompromise (risk of opportunistic infection). Immunosuppressants — complex pharmacodynamic interaction.

Clinical and phytochemical data

Used part

Fruiting body; SPG (schizophyllan) derived from fermentation of mycelium

Primary active compounds

  • Schizophyllan / SPG / Sizofiran (beta-1,3-glucan with beta-1,6-branching)

  • Glucans

  • Mannoproteins

Mechanism of action

Schizophyllan activates macrophages and NK cells via Dectin-1 receptor; upregulates IL-2, IFN-γ, TNF-α. Augments T-lymphocyte and dendritic cell function. Anti-tumour mechanism involves host-mediated immunostimulation rather than direct cytotoxicity. TLR-2/Dectin-1 co-activation amplifies innate immune signalling cascades.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Schizophyllan (SPG/sizofiran) is approved for clinical use in Japan as an IV immunomodulator in cervical cancer; oral bioavailability data for polysaccharide fractions remain unavailable. In vivo biodegradation and metabolism of beta-glucans reviewed in Chen X et al. (2022), Front Vet Sci [1]. Oral bioavailability of high-MW schizophyllan is very limited; clinical use is parenteral (intramuscular or intratumoral). Oral formulations active at mucosal immune level.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Schizophyllan (SPG) is a high-molecular-weight β-glucan; following clinical (IV/IM) administration in Japan, it distributes to spleen, lymph nodes, and tumour-associated lymphatics. Oral bioavailability is poor; clinically relevant distribution data applies to parenteral routes only. No meaningful systemic oral distribution.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Partially hydrolysed by gut glucanases; absorbed fractions undergo hepatic metabolism.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Primarily fecal for oral forms; renal for parenteral metabolites.

Safety and interactions

Drug interactions

Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.

Toxicity

SPG parenteral: well-tolerated in clinical trials; injection site reactions. Risk of opportunistic infection (Schizophyllum commune sino-pulmonary infection) in immunocompromised individuals — this is a documented pathogen, not just a theoretical risk.

Special precautions

Pregnancy

Insufficient human clinical data. Avoid during pregnancy.

Lactation

No data available. Avoid during breastfeeding.

Hepatic impairment

No hepatotoxicity documented. Standard monitoring recommended.

Renal impairment

No specific risk identified. No dose adjustment data.

Sources and references

  1. [1] - Okamura K., "Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer.", Cancer, 1986, PMID: 2941141
  2. [2] - Fujimoto S., "Clinical efficacies of schizophyllan (SPG) on advanced gastric cancer.", Nihon Geka Gakkai Zasshi, 1989, PMID: 2531270
  3. [3] - Borchers AT., "Mushrooms, tumors, and immunity.", Proc Soc Exp Biol Med, 1999, PMID: 10460691
  4. [4] - Oguma T., "Clinical characteristics of allergic bronchopulmonary mycosis caused by Schizophyllum commune.", Clin Transl Allergy, 2024, PMID: 38282191
  5. [5] - Hoenigl M., "Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology.", Lancet Infect Dis, 2021, PMID: 33606997

Additional source links

Continue browsing